JP2016516076A5 - - Google Patents

Download PDF

Info

Publication number
JP2016516076A5
JP2016516076A5 JP2016503654A JP2016503654A JP2016516076A5 JP 2016516076 A5 JP2016516076 A5 JP 2016516076A5 JP 2016503654 A JP2016503654 A JP 2016503654A JP 2016503654 A JP2016503654 A JP 2016503654A JP 2016516076 A5 JP2016516076 A5 JP 2016516076A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
insulin
chain
long
cooh
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016503654A
Other languages
English (en)
Japanese (ja)
Other versions
JP6755175B2 (ja
JP2016516076A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2014/055533 external-priority patent/WO2014147141A1/en
Publication of JP2016516076A publication Critical patent/JP2016516076A/ja
Publication of JP2016516076A5 publication Critical patent/JP2016516076A5/ja
Application granted granted Critical
Publication of JP6755175B2 publication Critical patent/JP6755175B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016503654A 2013-03-20 2014-03-19 インスリン投薬レジメン Active JP6755175B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP13160194.0 2013-03-20
EP13160194 2013-03-20
US201361804363P 2013-03-22 2013-03-22
US61/804,363 2013-03-22
PCT/EP2014/055533 WO2014147141A1 (en) 2013-03-20 2014-03-19 Insulin dosing regimen

Publications (3)

Publication Number Publication Date
JP2016516076A JP2016516076A (ja) 2016-06-02
JP2016516076A5 true JP2016516076A5 (enExample) 2017-04-27
JP6755175B2 JP6755175B2 (ja) 2020-09-16

Family

ID=47900938

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016503654A Active JP6755175B2 (ja) 2013-03-20 2014-03-19 インスリン投薬レジメン

Country Status (5)

Country Link
US (4) US20160296602A1 (enExample)
EP (1) EP2976096B1 (enExample)
JP (1) JP6755175B2 (enExample)
CN (1) CN105188736A (enExample)
WO (1) WO2014147141A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090074882A1 (en) 2005-12-28 2009-03-19 Novo Nordisk A/S Insulin compositions and method of making a composition
CA2738615A1 (en) 2008-10-30 2010-05-06 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
JP6049625B2 (ja) 2010-10-27 2016-12-21 ノヴォ ノルディスク アー/エス 様々な注射間隔を用いて施されるインスリン注射を使用する、真性糖尿病の治療
WO2014177623A1 (en) 2013-04-30 2014-11-06 Novo Nordisk A/S Novel administration regime
MA46890A (fr) 2016-11-28 2021-04-28 Novo Nordisk As Insuline degludec pour l'amélioration du contrôle glycémique et la réduction des complications du diabète aigu et à long terme
WO2018096164A1 (en) * 2016-11-28 2018-05-31 Novo Nordisk A/S Insulin degludec for treating diabetes
JP7193455B2 (ja) * 2016-11-28 2022-12-20 ノヴォ ノルディスク アー/エス 心血管状態におけるインスリンデグルデク
CN110248964B (zh) 2017-02-01 2024-08-27 诺和诺德股份有限公司 促凝血抗体
JOP20190273A1 (ar) 2017-05-26 2019-11-24 Lilly Co Eli مركب إنسولين معالج بأسيل
TWI797133B (zh) 2017-06-09 2023-04-01 丹麥商諾佛 儂迪克股份有限公司 用於經口投予的固體組成物
WO2020002428A1 (en) * 2018-06-26 2020-01-02 Novo Nordisk A/S System providing dose recommendations for basal insulin titration
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
US11220554B2 (en) 2018-09-07 2022-01-11 Novo Nordisk A/S Procoagulant antibodies
SG11202106168VA (en) 2018-12-11 2021-07-29 Sanofi Sa Insulin analogs having reduced insulin receptor binding affinity
CN114096269B (zh) 2019-07-12 2024-06-11 诺和诺德股份有限公司 高浓度胰岛素制剂

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101186851B1 (ko) * 2003-08-05 2012-10-02 노보 노르디스크 에이/에스 신규의 인슐린 유도체
KR101159559B1 (ko) * 2003-08-05 2012-06-26 노보 노르디스크 에이/에스 신규의 인슐린 유도체
US20090074882A1 (en) * 2005-12-28 2009-03-19 Novo Nordisk A/S Insulin compositions and method of making a composition
CN101454019A (zh) * 2006-04-12 2009-06-10 百达尔公司 速效和长效胰岛素联合制剂
WO2008152106A1 (en) * 2007-06-13 2008-12-18 Novo Nordisk A/S Pharmaceutical formulation comprising an insulin derivative
CN101784563B (zh) * 2007-08-15 2015-02-04 诺沃-诺迪斯克有限公司 具有包括含亚烷基二醇的氨基酸的重复单位的酰基部分的胰岛素
CA2738615A1 (en) * 2008-10-30 2010-05-06 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
EP2569002B1 (en) * 2010-05-10 2016-10-26 Novo Nordisk A/S Process for the preparation of insulin-zinc complexes
AU2011202239C1 (en) * 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
SI2632478T1 (sl) * 2010-10-27 2019-11-29 Novo Nordisk As Zdravljenje sladkorne bolezni z uporabo inzulinskih injekcij, ki se dajejo v različnih injicirnih intervalih
JP6110312B2 (ja) * 2011-02-01 2017-04-05 ノヴォ ノルディスク アー/エス インスリンの精製
AU2012223282B2 (en) * 2011-03-01 2017-02-02 Nutrition 21, Llc Compositions of insulin and chromium for the treatment and prevention of diabetes, hypoglycemia and related disorders
WO2013164375A1 (en) * 2012-05-01 2013-11-07 Novo Nordisk A/S Pharmaceutical composition
WO2014177623A1 (en) * 2013-04-30 2014-11-06 Novo Nordisk A/S Novel administration regime

Similar Documents

Publication Publication Date Title
JP2016516076A5 (enExample)
DK1965823T3 (en) Methods of administering hypoglycemics
RU2011117645A (ru) Лечение сахарного диабета с использованием инъекций инсулина с частотой менее одного раза в день
Melson et al. Future therapies for obesity
AU2016202917B2 (en) Treating diabetes melitus using insulin injections administered with varying injection intervals
US20100087365A1 (en) Pharmaceutical Compositions of Hglp-1, Exendin-4 and Analogs Thereof
RU2012123739A (ru) Фармацевтическая композиция, содержащая агонист гпп-1 и метионин
JP2014520798A5 (enExample)
RU2014126244A (ru) Лекарственные средства, содержащие аминокислотные последовательности инсулина
RU2013139651A (ru) Новые соединения, влияющие на пищевое поведение
AR071990A1 (es) Compuesto de insulina lispro pegilada, su uso para la manufactura de un medicamento util para el tratamiento de hipoglicemia o diabetes , composicion farmaceutica que lo comprende y proceso para elaborar dicho compuesto
JP2011241213A5 (enExample)
JP2011001381A (ja) Glp−1医薬組成物
WO2009020802A2 (en) Treatment for obesity
JP2014520798A (ja) ポリエチレングリコールまたはその誘導体でpeg化されたエキセンジン−4類似体、その調製法、および活性成分としてこれを含有する、糖尿病を予防または処置するための薬学的組成物
MX2012006744A (es) Tiazolidinadionas reguladores de receptores activados por proliferador de peroxisoma (ppar) y combinaciones para el tratamiento de diabetes mellitus y otras enfermedades metabolicas.
US20040037826A1 (en) Combined use of a modulator of CD3 and a GLP-1 compound
Brandt et al. Are peptide conjugates the golden therapy against obesity?
JP2015517458A5 (enExample)
Edmonds et al. Oral GLP-1 modulators for the treatment of diabetes
RU2014147674A (ru) Фармацевтическая композиция
CN110013542B (zh) 一种预防/治疗突触核蛋白病的药物及多肽类似物
Woo A review of the clinical efficacy and safety of insulin degludec and glargine 300 U/mL in the treatment of diabetes mellitus
JP2014500244A5 (enExample)
JP6049625B2 (ja) 様々な注射間隔を用いて施されるインスリン注射を使用する、真性糖尿病の治療